Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients-Reference-Cited by-同舟云学术

Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

Published:2013-06-15 Issue:4 Volume:162 Page:474-482
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Caballero-Velázquez Teresa¹,López-Corral Lucia²,Encinas Cristina³,Castilla-Llorente Cristina⁴,Martino Rodrigo⁵,Rosiñol Laura⁶,Sampol Antonia⁷,Caballero Dolores²,Serrano David³,Heras Inmaculada⁴,San Miguel Jesús²,Pérez-Simón José A.

Affiliation:

1. Servicio de Hematología; Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla; Instituto de Biomedicina de Sevilla (IBIS); Sevilla; Spain

2. Servicio de Hematología; Hospital Clínico Universitario de Salamanca; IBSAL; IBMCC (USAL-CSIC); Salamanca; Spain

3. Servicio de Hematología; Hospital Gregorio Marañon; Madrid; Spain

4. Hospital Morales Messeguer; Murcia; Spain

5. Hospital Santa Creu y Sant Pau; Barcelona; Spain

6. Hospital Clinic IDIBAPS Barcelona; Barcelona; Spain

7. Hospital Son Dureta; Palma de Mallorca; Spain

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12410/fullpdf